Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| National Eye Institute (NEI) | Other Grant/Funding Number | 2R01EY012893-06A1 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Eye Institute (NEI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Investigational Phase of the Study:
The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with retinitis pigmentosa.
Post-Approval Phase of the Study:
To collect post-approval data in order to monitor the ongoing safety and reliability of the Argus II System
During the post-approval phase, subjects will undergo annual eye exams, assessments of medical status and adverse events, and measurement of stimulation thresholds. In addition, at the mutual agreement of the investigator and the subject, subjects will have the option of participating in psychophysical research which could occur as frequently as monthly. Functional tests at 10 years: photographic flash, square localization, direction of motion and grating visual acuity.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Implant of Argus II Retinal Prosthesis | Other | This is a single group study where the status and performance of the implanted eye prior to surgery serves as the comparator. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Implant of Argus II Retinal Prosthesis | Device | epiretinal implantation of device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Visual Acuity | Grating Visual Acuity is performed at Baseline and at various timepoints throughout the study. As of the 10 year final testing, the total number of subjects that were able to score on the logMAR scale are indicated below. The device has a scale from 1.6 to 2.9 logMAR. Maximum likelihood estimation of visual acuity is based on BEST-PEST algorithm. | 10 years |
| Number of Participants With Adverse Events | Evaluate ocular adverse events reported for all subjects from day of implant through 10 years of study participation | 10 years |
| Measure | Description | Time Frame |
|---|---|---|
| Massof Activity Inventory | The Massof Activity Inventory measures changes in ability to perform activities of daily living in terms of Goals and Tasks in logits (log-odds units). A logit scale is an equal interval linear scale that represents probability values in terms of real numbers. There is no minimum or maximum scale used in this testing. In this case, a Rasch distribution (using an Andrich rating model) was used to find the maximum likelihood of difficulty of achieving Goals and Tasks, represented in logits. The change in mean logit value between baseline and the 36Month visit for each subject are provided below along with the 95% confidence interval (CI) for the change. A positive change in the Goals or Tasks score which is greater than 0.2 (with a CI less than the mean logit value), is interpreted as a clinically significant increase in functional ability (better outcome). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Optic Nerve disease
Diseases or conditions that effect retinal function including but not limited to:
Diseases or conditions that prevent adequate visualization of the retina including, but not limited to corneal degeneration that cannot be resolved before implant.
Diseases or conditions of the anterior segment that prevent the ability to adequately perform the physical examination including but not limited to trauma or lid malpositions.
Diseases of the ocular surface including but not limited to keratitis sicca.
An ocular condition that predisposes the subject to eye rubbing.
Any disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocols, including:
Pregnancy
Subject has another active implantable device (e.g. cochlear implant), or any form of metallic implant in the head
Conjunctival thinning which may predispose the subject to conjunctival erosion in the area where the implant will be installed extra-ocularly.
Subject is participating in another investigational drug or device study that may conflict with the objectives, follow-up or testing of this study
Any health concern that makes general anesthesia inadvisable.
Subject has unrealistic expectations of the implant.
Known allergy or contraindication to anticipated pre-operative, intra-operative or post-operative medications.
Conditions likely to limit life to less than 1 year from the time of screening.
Diseases or conditions that, in the judgement of the surgeon, impede the ability to implant the device or would prevent the system from functioning for the duration of the study (e.g. strabismus)
Axial eye length <21.5 mm or >26.0 mm in the implanted eye as measured by ultrasound (US only)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anne-Marie Ripley | Second Sight Medical Products | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Doheny Eye Institute | Los Angeles | California | 90033 | United States | ||
| University of California San Francisco |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22260934 | Background | Weiland JD, Faraji B, Greenberg RJ, Humayun MS, Shellock FG. Assessment of MRI issues for the Argus II retinal prosthesis. Magn Reson Imaging. 2012 Apr;30(3):382-9. doi: 10.1016/j.mri.2011.12.005. Epub 2012 Jan 20. | |
| 22244176 | Result | Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Sahel JA, Stanga PE, Cideciyan AV, Duncan JL, Eliott D, Filley E, Ho AC, Santos A, Safran AB, Arditi A, Del Priore LV, Greenberg RJ; Argus II Study Group. Interim results from the international trial of Second Sight's visual prosthesis. Ophthalmology. 2012 Apr;119(4):779-88. doi: 10.1016/j.ophtha.2011.09.028. Epub 2012 Jan 11. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Implant of Argus II Retinal Prosthesis | This is a single group study where the status and performance of the implanted eye prior to surgery serves as the comparator. Argus II Retinal Stimulation System: epiretinal implantation of device |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Implant of Argus II Retinal Prosthesis | This is a single group study where the status and performance of the implanted eye prior to surgery serves as the comparator. Argus II Retinal Stimulation System: epiretinal implantation of device |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Visual Acuity | Grating Visual Acuity is performed at Baseline and at various timepoints throughout the study. As of the 10 year final testing, the total number of subjects that were able to score on the logMAR scale are indicated below. The device has a scale from 1.6 to 2.9 logMAR. Maximum likelihood estimation of visual acuity is based on BEST-PEST algorithm. | Posted | Count of Participants | Participants | 10 years |
|
|
10 years
Ocular events are reportable for this protocol from day of implant through the last study visit for each subject.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Single Arm | Single arm with fellow eye as comparator | 1 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Conjunctival dehiscence | Eye disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| 360 Circumferential Vitreous Band Traction | Eye disorders | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jessy Dorn, PhD, Director of Clinical and Scientific Affiars | Second Sight Medical Products, Inc. | 8188335089 | jdorn@secondsight.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP_ICF | Yes | Yes | Yes | Study Protocol, Statistical Analysis Plan, and Informed Consent Form | Jan 15, 2013 | Sep 24, 2019 | Prot_SAP_ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D012174 | Retinitis Pigmentosa |
| ID | Term |
|---|---|
| D015785 | Eye Diseases, Hereditary |
| D005128 | Eye Diseases |
| D058499 | Retinal Dystrophies |
| D012162 | Retinal Degeneration |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 3 years |
| Quality of Life - Tasks for Daily Living | Quality of life is being measured using the VisQOL survey. This instrument, developed by researchers at the University of Melbourne, Australia, is a vision and quality of life-related utility measure intended to evaluate healthcare interventions for the visually impaired. The utility score is a preference-based measure of vision-related quality of life (Dimension 7 score (Health Dimension Score (1=Best, 0=Worst)). It measures subjective quality of life on a scale of 0 to 1, where 0 represents worst possible quality of life and 1 represents perfect quality of life. | 3 years |
| Orientation and Mobility | Argus II System for orientation and mobility, each subject completed two tests (walking to a high-contrast "door" on the wall and following a straight line on the floor) at various timepoints throughout the study. Accuracy (percent of trials where the subject successfully reached the target) was measured with the device system ON and system OFF. Average % success rates across the analysis population are provided for each modality and for each test at the 60 month time point. | 5 years |
| Visual Function | Square localization (SL) and Direction of Motion (DOM) testing performed at specific protocol intervals. SL tests ability of subjects to locate high-contrast square on black screen. DOM tests ability of subjects to determine the direction a white bar is moving over a black screen. Each test is performed with the system ON and then compared to performance with the system OFF. Number of subjects who performed significantly better with the system ON is indicated below. | 10 years |
| Stability of Implant - 5 Years Post Implant | Stability of electrode array on the retina. Qualitative review of imaging: retinal and array landmarks compared from all time points post implant. | 5 years |
| Device Reliability | Number of participants with functional devices 10 years post implant | 10 years |
| San Francisco |
| California |
| 94143 |
| United States |
| Johns Hopkins, Wilmer Eye Institute | Baltimore | Maryland | 21205 | United States |
| Columbia University, Department of Ophthalmology, Edward S. Harkness Eye Institute | New York | New York | 10032 | United States |
| University of Pennsylvania, Scheie Eye Institute | Philadelphia | Pennsylvania | 19104 | United States |
| Wills Eye Hospital | Philadelphia | Pennsylvania | 19107 | United States |
| Retina Foundation of the Southwest | Dallas | Texas | 75231 | United States |
| Centre d'Investigation Clinique, Service d'Ophtalmologie, Quinze-Vingts National Eye Hospital, 28 rue de Charenton, 75557 Cedex 12 | Paris | France |
| Puerta de Hierro, Centro Medico, Centro de Retina | Zapopan | Jalisco | 51116 | Mexico |
| Clinique d'Ophthalmologie Hopitaux, Universitaires de Geneve 22 rue Alcide Jentzer 1205 | Geneva | Switzerland |
| Moorfields Eye Hospital, Vitreoretinal Research Unit | London | EC1V 2PD | United Kingdom |
| Manchester Royal Eye Hospital | Manchester | United Kingdom |
| 22661464 | Result | Barry MP, Dagnelie G; Argus II Study Group. Use of the Argus II retinal prosthesis to improve visual guidance of fine hand movements. Invest Ophthalmol Vis Sci. 2012 Aug 1;53(9):5095-101. doi: 10.1167/iovs.12-9536. |
| 20881025 | Result | Ahuja AK, Dorn JD, Caspi A, McMahon MJ, Dagnelie G, Dacruz L, Stanga P, Humayun MS, Greenberg RJ; Argus II Study Group. Blind subjects implanted with the Argus II retinal prosthesis are able to improve performance in a spatial-motor task. Br J Ophthalmol. 2011 Apr;95(4):539-43. doi: 10.1136/bjo.2010.179622. Epub 2010 Sep 29. |
| 34706764 | Derived | Arevalo JF, Al Rashaed S, Alhamad TA, Al Kahtani E, Al-Dhibi HA; KKESH Collaborative Retina Study Group. Argus II retinal prosthesis for retinitis pigmentosa in the Middle East: The 2015 Pan-American Association of Ophthalmology Gradle Lecture. Int J Retina Vitreous. 2021 Oct 27;7(1):65. doi: 10.1186/s40942-021-00324-6. |
| 25414187 | Derived | Sabbah N, Authie CN, Sanda N, Mohand-Said S, Sahel JA, Safran AB. Importance of eye position on spatial localization in blind subjects wearing an Argus II retinal prosthesis. Invest Ophthalmol Vis Sci. 2014 Nov 20;55(12):8259-66. doi: 10.1167/iovs.14-15392. |
| 24049718 | Derived | Ahuja AK, Yeoh J, Dorn JD, Caspi A, Wuyyuru V, McMahon MJ, Humayun MS, Greenberg RJ, Dacruz L. Factors Affecting Perceptual Threshold in Argus II Retinal Prosthesis Subjects. Transl Vis Sci Technol. 2013 Apr;2(4):1. doi: 10.1167/tvst.2.4.1. Epub 2013 Apr 12. |
| 24013578 | Derived | de Juan E Jr, Spencer R, Barale PO, da Cruz L, Neysmith J. Extraction of retinal tacks from subjects implanted with an epiretinal visual prosthesis. Graefes Arch Clin Exp Ophthalmol. 2013 Oct;251(10):2471-6. doi: 10.1007/s00417-013-2452-y. Epub 2013 Sep 8. |
| 23611993 | Derived | Stronks HC, Barry MP, Dagnelie G. Electrically elicited visual evoked potentials in Argus II retinal implant wearers. Invest Ophthalmol Vis Sci. 2013 Jun 6;54(6):3891-901. doi: 10.1167/iovs.13-11594. |
| 23544203 | Derived | Dorn JD, Ahuja AK, Caspi A, da Cruz L, Dagnelie G, Sahel JA, Greenberg RJ, McMahon MJ; gus II Study Group. The Detection of Motion by Blind Subjects With the Epiretinal 60-Electrode (Argus II) Retinal Prosthesis. JAMA Ophthalmol. 2013 Feb;131(2):183-9. doi: 10.1001/2013.jamaophthalmol.221. |
| 23500412 | Derived | Ahuja AK, Behrend MR. The Argus II retinal prosthesis: factors affecting patient selection for implantation. Prog Retin Eye Res. 2013 Sep;36:1-23. doi: 10.1016/j.preteyeres.2013.01.002. Epub 2013 Mar 14. |
| 22761263 | Derived | Olson JL, Velez-Montoya R, Mandava N, Stoldt CR. Intravitreal silicon-based quantum dots as neuroprotective factors in a model of retinal photoreceptor degeneration. Invest Ophthalmol Vis Sci. 2012 Aug 17;53(9):5713-21. doi: 10.1167/iovs.12-9745. |
| 22447863 | Derived | Perez Fornos A, Sommerhalder J, da Cruz L, Sahel JA, Mohand-Said S, Hafezi F, Pelizzone M. Temporal properties of visual perception on electrical stimulation of the retina. Invest Ophthalmol Vis Sci. 2012 May 4;53(6):2720-31. doi: 10.1167/iovs.11-9344. |
| Participants |
|
| Age, Continuous | Mean | Full Range | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
| Primary | Number of Participants With Adverse Events | Evaluate ocular adverse events reported for all subjects from day of implant through 10 years of study participation | Posted | Number | participants | 10 years |
|
|
|
| Secondary | Massof Activity Inventory | The Massof Activity Inventory measures changes in ability to perform activities of daily living in terms of Goals and Tasks in logits (log-odds units). A logit scale is an equal interval linear scale that represents probability values in terms of real numbers. There is no minimum or maximum scale used in this testing. In this case, a Rasch distribution (using an Andrich rating model) was used to find the maximum likelihood of difficulty of achieving Goals and Tasks, represented in logits. The change in mean logit value between baseline and the 36Month visit for each subject are provided below along with the 95% confidence interval (CI) for the change. A positive change in the Goals or Tasks score which is greater than 0.2 (with a CI less than the mean logit value), is interpreted as a clinically significant increase in functional ability (better outcome). | Data for all 14 US subjects analyzed | Posted | Mean | 95% Confidence Interval | Logit scale | 3 years |
|
|
|
| Secondary | Quality of Life - Tasks for Daily Living | Quality of life is being measured using the VisQOL survey. This instrument, developed by researchers at the University of Melbourne, Australia, is a vision and quality of life-related utility measure intended to evaluate healthcare interventions for the visually impaired. The utility score is a preference-based measure of vision-related quality of life (Dimension 7 score (Health Dimension Score (1=Best, 0=Worst)). It measures subjective quality of life on a scale of 0 to 1, where 0 represents worst possible quality of life and 1 represents perfect quality of life. | 30 subjects were analyzed comparing Baseline visit to the last visit when VisQOL was performed. | Posted | Mean | Standard Deviation | units on a scale | 3 years |
|
|
|
| Secondary | Orientation and Mobility | Argus II System for orientation and mobility, each subject completed two tests (walking to a high-contrast "door" on the wall and following a straight line on the floor) at various timepoints throughout the study. Accuracy (percent of trials where the subject successfully reached the target) was measured with the device system ON and system OFF. Average % success rates across the analysis population are provided for each modality and for each test at the 60 month time point. | Data for all 14 US subjects analyzed | Posted | Mean | Standard Deviation | percentage of successful trials | 5 years |
|
|
|
| Secondary | Visual Function | Square localization (SL) and Direction of Motion (DOM) testing performed at specific protocol intervals. SL tests ability of subjects to locate high-contrast square on black screen. DOM tests ability of subjects to determine the direction a white bar is moving over a black screen. Each test is performed with the system ON and then compared to performance with the system OFF. Number of subjects who performed significantly better with the system ON is indicated below. | Data available only on 13 of the 14 US subjects | Posted | Count of Participants | Participants | 10 years |
|
|
|
| Secondary | Stability of Implant - 5 Years Post Implant | Stability of electrode array on the retina. Qualitative review of imaging: retinal and array landmarks compared from all time points post implant. | Data for all 14 US subjects analyzed | Posted | Count of Participants | Participants | 5 years |
|
|
|
| Secondary | Device Reliability | Number of participants with functional devices 10 years post implant | Posted | Count of Participants | Participants | 10 years |
|
|
|
| 30 |
| 13 |
| 30 |
| 28 |
| 30 |
| Conjunctival erosion | Eye disorders | Non-systematic Assessment |
|
| Corneal melt | Eye disorders | Non-systematic Assessment |
|
| Endophthalmitis - infective | Eye disorders | Non-systematic Assessment |
|
| Epiretinal membrane | Eye disorders | Non-systematic Assessment |
|
| Hypotony | Eye disorders | Non-systematic Assessment |
|
| Iris rubeosis | Eye disorders | Non-systematic Assessment |
|
| Keratitis - infective | Eye disorders | Non-systematic Assessment |
|
| Migration (extra-ocular) of intraocular silicone oil | Eye disorders | Non-systematic Assessment |
|
| Re-tack | Eye disorders | Non-systematic Assessment | Re-tack to hold the device in place on the retina |
|
| Retinal detachment - rhegmatogenous | Eye disorders | Non-systematic Assessment |
|
| Retinal detachment - tractional and serous | Eye disorders | Non-systematic Assessment |
|
| Retinal tear | Eye disorders | Non-systematic Assessment |
|
| Uveitis | Eye disorders | Non-systematic Assessment |
|
| Choroidal detachment | Eye disorders | Non-systematic Assessment |
|
| Choroidal effusion | Eye disorders | Non-systematic Assessment |
|
| Conjunctival congestion | Eye disorders | Non-systematic Assessment |
|
| Conjunctival cyst | Eye disorders | Non-systematic Assessment |
|
| Conjunctival dehiscence | Eye disorders | Non-systematic Assessment |
|
| Conjunctival erosion | Eye disorders | Non-systematic Assessment |
|
| Conjunctivitis - inflammatory | Eye disorders | Non-systematic Assessment |
|
| Corneal abrasion | Eye disorders | Non-systematic Assessment |
|
| Corneal dryness | Eye disorders | Non-systematic Assessment |
|
| Corneal epithelial defect | Eye disorders | Non-systematic Assessment |
|
| Corneal fold | Eye disorders | Non-systematic Assessment |
|
| Corneal opacity | Eye disorders | Non-systematic Assessment |
|
| Corneal Suture Broken | Eye disorders | Non-systematic Assessment |
|
| Corneal vascularization | Eye disorders | Non-systematic Assessment |
|
| Decrease in light perception | Eye disorders | Non-systematic Assessment |
|
| Elective revision surgery | Eye disorders | Non-systematic Assessment | Better placement of array on retina |
|
| Epiphora | Eye disorders | Non-systematic Assessment |
|
| Epiretinal membrane | Eye disorders | Non-systematic Assessment |
|
| Fibrosis around retinal tack | Eye disorders | Non-systematic Assessment |
|
| Filamentary keratitis | Eye disorders | Non-systematic Assessment |
|
| Foreign Body Sensation | Eye disorders | Non-systematic Assessment |
|
| Headache | Eye disorders | Non-systematic Assessment | Adjudicated as device related |
|
| High IOP | Eye disorders | Non-systematic Assessment |
|
| Hyphema | Eye disorders | Non-systematic Assessment |
|
| Hypotony | Eye disorders | Non-systematic Assessment |
|
| Inflammation - ocular | Eye disorders | Non-systematic Assessment |
|
| Irregular pupil | Eye disorders | Non-systematic Assessment |
|
| Keratic Precipitates | Eye disorders | Non-systematic Assessment |
|
| Nausea | General disorders | Non-systematic Assessment | Adjudicated as device or procedure related |
|
| Nystagmus increase | Eye disorders | Non-systematic Assessment |
|
| Ocular fibrin | Eye disorders | Non-systematic Assessment |
|
| Pain - ocular | Eye disorders | Non-systematic Assessment |
|
| Pre-retinal hemorrhage | Eye disorders | Non-systematic Assessment |
|
| Proliferative Vitreoretinopathy | Eye disorders | Non-systematic Assessment |
|
| Ptosis | Eye disorders | Non-systematic Assessment |
|
| Retinal Break/Tear | Eye disorders | Non-systematic Assessment |
|
| Retinal detachment - tractional | Eye disorders | Non-systematic Assessment |
|
| Retinal folds | Eye disorders | Non-systematic Assessment |
|
| Retinal Thickening - cystoid macular edema (CME) | Eye disorders | Non-systematic Assessment |
|
| Retinal Thickening - without cystic changes | Eye disorders | Non-systematic Assessment |
|
| Retinoschisis | Eye disorders | Non-systematic Assessment |
|
| Revision Surgery - tack replacement | Eye disorders | Non-systematic Assessment |
|
| Rubeosis | Eye disorders | Non-systematic Assessment |
|
| Scleral graft displacement or reabsorption | Eye disorders | Non-systematic Assessment |
|
| Scleritis | Eye disorders | Non-systematic Assessment |
|
| Suture irritation | General disorders | Non-systematic Assessment | Associated with surgical procedure |
|
| Uveitis | Eye disorders | Non-systematic Assessment |
|
| Vertigo | General disorders | Non-systematic Assessment |
|
| Vitreous hemorrhage | Eye disorders | Non-systematic Assessment |
|
Not provided
Not provided
| D012164 |
| Retinal Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| Title | Measurements |
|---|---|
|
| S4-Goals |
|
| S5-Goals |
|
| S6-Goals |
|
| S7-Goals |
|
| S8-Goals |
|
| S9-Goals |
|
| S10-Goals |
|
| S11-Goals |
|
| S12-Goals |
|
| S13-Goals |
|
| S14 -Goals |
|
| S1-Tasks |
|
| S2-Tasks |
|
| S3-Tasks |
|
| S4-Tasks |
|
| S5-Tasks |
|
| S6-Tasks |
|
| S7-Tasks |
|
| S8-Tasks |
|
| S9-Tasks |
|
| S10-Tasks |
|
| S11-Tasks |
|
| S12-Tasks |
|
| S13-Tasks |
|
| S14-Tasks |
|
|
| Average % system ON-Line Task |
|
|
| Average % system OFF-Line Task |
|
|
| Title | Measurements |
|---|---|
|